Zydus Lifesciences Limited (NSE:ZYDUSLIFE)

Market Cap	912.30B -2.7%
Revenue (ttm)	260.89B +17.3%
Net Income	49.38B +8.9%
EPS	49.07 +9.0%
Shares Out	1.01B
PE Ratio	18.47
Forward PE	21.32
Dividend	11.00 (1.21%)
Ex-Dividend Date	Jul 25, 2025

Volume	234,313
Average Volume	734,963
Open	910.00
Previous Close	910.45
Day's Range	903.55 - 914.15
52-Week Range	795.00 - 1,059.05
Beta	0.37
RSI	51.72
Earnings Date	Feb 9, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 27,917
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZYDUSLIFE

Financial Performance

In fiscal year 2025, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.